Diet, activity and muscle health in adults with inclusion body myositis
Looks at how diet relates to muscle health in adults with inclusion body myositis.
Key facts
- Who runs it
- Manchester Metropolitan University
- Where
- Manchester, United KingdomSee the site
- Trial code
- Registry title
- IBM Dietary Surveillance Study
- Status
- Not yet recruiting
- People taking part
- 47 people, planned
- Started
- 30 Apr 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Whole-Body Dual-Energy X-ray Absorptiometry
- Anthropometry
- Capillary Blood Sampling
- Indirect Calorimetry
- Magnetic Resonance Imaging
- Dynamometry
- Behavioural Monitoring
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with inclusion body myositis (IBM), a muscle disease, and healthy adults to compare with them. It studies diet, physical activity and muscle health.
- Age
- 40 years and older.
- Sex
- All sexes.
- Disease stage
- People with IBM need a Definite or Probable IBM diagnosis under the revised European Neuromuscular Centre 2013 criteria. They must be able to walk short distances, with or without a cane or frame. They must be able to eat solid or softened food, not only by tube. Healthy volunteers must be generally healthy, with no known muscle or metabolic disease. They are paired with IBM participants of similar age and activity level.
- Earlier treatment
- People cannot join if they were in an interventional trial in the past 3 months. For people with IBM, this means a trial that could affect diet, activity or muscle metabolism.
Main reasons for not taking part
- Other nerve-muscle or metabolic disorders.
- Feeding only by tube or drip because of severe swallowing problems.
- Conditions that make scans or tests unsafe, such as severe osteoporosis (T-score < -3.0), breathing problems or severe claustrophobia.
- Not able to understand written or spoken English.
- Healthy volunteers who live in the same household as an IBM participant.
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Diagnosis of Inclusion Body Myositis: As defined by the revised European Neuromuscular Centre 2013 diagnostic criteria (Definite or Probable IBM)
- Age: Adults aged ≥40 years at the time of consent
- Ability to Provide Informed Consent: Participants must be cognitively capable of providing written, informed consent
- Disease Progression: Participants must be able to walk short distances, with or without the use of an assistive aid (e.g., a cane or frame) for balance, so that they can undertake study procedures without safety concerns. Must be able to consume solid or modified-texture food, with or without dysphagia adaptations (i.e., not exclusively tube-fed)
- Willingness to Participate: Willing to attend study visits and comply with all study procedures
- Disease-Free: Control participants must be generally healthy, with no known myopathies or metabolic diseases. They must not have any conditions that, in the judgement of a clinician, would compromise their safety, impair their ability to complete study procedures, or influence study outcomes
- Age: Adults aged ≥40 years at the time of consent
- Ability to Provide Written Informed Consent
- Willingness to Participate
- Matched to IBM participants according to their age and physical activity levels
Who cannot take part
- Coexisting Neuromuscular or Metabolic Disorders: Presence of other neuromuscular or metabolic disorders that may confound the outcomes of interest
- Contraindications to any Study Procedures: Any condition preventing safe completion of key assessments. For instance: severe osteoporosis contraindicating DXA scanning (T-score < -3.0), respiratory conditions, severe claustrophobia, severe cognitive impairments or communication barriers that may impair participant ability to comply with study procedures
- Diagnosed neuromuscular or metabolic Disorder
- Severe Dysphagia: Participants requiring exclusive enteral or parenteral feeding, which would prevent participation in dietary intake assessments
- Enrolment in an interventional trial within the past 3 months: Participation in an interventional study within the past 3 months involving interventions that may affect dietary habits, physical activity, or muscle metabolism
- Logistical Concerns: Any other logistical concern, as judged by the CI, that would compromise participant safety or the integrity of study data
- English Comprehension: Participants will be excluded if they are unable to understand written or verbal English to a degree that would impair their ability to provide informed consent or fully understand the study procedures
- Enrolment in an interventional trial within the past 3 months
- Contraindications to any study procedures such as those listed for IBM participants (e.g., DXA, MRI)
- Logistical or safety concerns, as judged by the research team
- To minimise dietary overlap, individuals living in the same household as an IBM participant will not be eligible
- Do not meet the physical activity criteria to be appropriately matched to an IBM participant
- Unable to understand written or verbal English
Where in United Kingdom
- Manchester Metropolitan University Institute of SportManchester, United KingdomContact: Dr Paul T MorganNot yet recruiting
About the trial
What the trial wants to find out
The goal of this observational study is to understand how diet may influence the disease characteristics of inclusion body myositis (IBM). Research findings will help determine whether dietary factors could play a role in managing IBM.
Read full original descriptionShow less
The study aims to answer the question: Does diet affect the muscle health and functional ability of people living with IBM?
Researchers will compare adults with IBM to healthy volunteers aged 40 years and older. This comparison will help to identify which findings are related to normal ageing and which are specific to IBM.
Participants will:
Attend an initial screening visit at the Manchester Metropolitan University Institute of Sport to confirm eligibility and explain study procedures.
Complete four weeks of home-based monitoring, including dietary records, physical activity monitoring, and questionnaires about lifestyle and symptoms.
Attend a second university visit for assessments of body composition, metabolism, and muscle function.
The 2 groups in the trial
- IBM
Individuals living with Inclusion Body Myositis
Treatment: Whole-Body Dual-Energy X-ray Absorptiometry, Anthropometry, Capillary Blood Sampling, Indirect Calorimetry, Magnetic Resonance Imaging, Dynamometry, and Behavioural Monitoring
- Healthy Controls
Adults without diagnosed neuromuscular or relevant chronic disease, matched to participants with IBM by age, sex, and habitual physical activity level
Treatment: Whole-Body Dual-Energy X-ray Absorptiometry, Anthropometry, Capillary Blood Sampling, Indirect Calorimetry, Magnetic Resonance Imaging, Dynamometry, and Behavioural Monitoring
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Surveying the Dietary Intake, Physical Activity Patterns, Muscle Strength and Morphology of Adults With Inclusion Body Myositis
- Plain-language title
- Diet, activity and muscle health in adults with inclusion body myositisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 17 April 2026